Cubist Systematic Strategies LLC Invests $2.56 Million in uniQure N.V. $QURE

Key Points

• Cubist Systematic Strategies LLC has invested approximately $2.56 million in uniQure N.V., acquiring 241,684 shares, which represents 0.44% of the company's stock.
• Several large investors have recently increased their stakes in uniQure, with institutional ownership now at 78.83%.
• Analysts have a consensus "Buy" rating for uniQure, with price targets ranging from $28.00 to $70.00, indicating strong potential upside for the stock.

Cubist Systematic Strategies LLC acquired a new position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 241,684 shares of the biotechnology company's stock, valued at approximately $2,562,000. Cubist Systematic Strategies LLC owned 0.44% of uniQure as of its most recent SEC filing.

Several other large investors also recently modified their holdings of QURE. Wells Fargo & Company MN grew its position in shares of uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock worth $217,000 after buying an additional 1,503 shares during the period. Tudor Investment Corp ET AL grew its position in uniQure by 5.9% in the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock valued at $438,000 after purchasing an additional 1,371 shares during the period. Northern Trust Corp grew its position in uniQure by 2.1% in the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after purchasing an additional 1,923 shares during the period. BNP Paribas Financial Markets grew its position in uniQure by 9.6% in the 4th quarter. BNP Paribas Financial Markets now owns 468,357 shares of the biotechnology company's stock valued at $8,271,000 after purchasing an additional 41,166 shares during the period. Finally, Balyasny Asset Management L.P. grew its position in uniQure by 53.8% in the 4th quarter. Balyasny Asset Management L.P. now owns 359,173 shares of the biotechnology company's stock valued at $6,343,000 after purchasing an additional 125,682 shares during the period. Institutional investors and hedge funds own 78.83% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Chardan Capital reissued a "buy" rating and issued a $35.00 price target on shares of uniQure in a research report on Friday, August 29th. Guggenheim reissued a "buy" rating and issued a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. Mizuho raised shares of uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 price target for the company in a research report on Thursday, August 14th. HC Wainwright reissued a "buy" rating and issued a $70.00 price target on shares of uniQure in a research report on Friday. Finally, Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $37.45.

Insider Activity at uniQure

In other news, Director Jack Kaye sold 2,112 shares of uniQure stock in a transaction on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the sale, the director directly owned 20,439 shares in the company, valued at $295,343.55. The trade was a 9.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David D. Meek sold 2,112 shares of uniQure stock in a transaction on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the sale, the director owned 34,190 shares in the company, valued at $494,045.50. The trade was a 5.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,144 shares of company stock worth $322,426. 4.79% of the stock is owned by company insiders.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $17.95 on Friday. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The stock's fifty day simple moving average is $14.98 and its two-hundred day simple moving average is $13.80. uniQure N.V. has a 1-year low of $4.45 and a 1-year high of $19.18. The stock has a market cap of $984.92 million, a PE ratio of -4.58 and a beta of 0.14.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The business had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5.00 million. As a group, analysts forecast that uniQure N.V. will post -3.75 EPS for the current fiscal year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.